G. Rodriguez

发表

A Phase II Trial of DaunoXome, Liposome‐ Encapsulated Daunorubicin, in Patients with Metastatic Adenocarcinoma of the Colon

D. V. Von Hoff, M. Rothenberg, N. Peacock, 1994, American journal of clinical oncology.

Phase I and pharmacokinetic trial of weekly CPT-11.

G. Weiss, S. Hilsenbeck, H. Burris, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.

D. V. Von Hoff, M. Villalona-Calero, L. Schaaf, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors

D. V. Von Hoff, L. Smith, H. Burris, 2004, Investigational New Drugs.

A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea.

G. Weiss, D. V. Von Hoff, S. Hilsenbeck, 1998, Blood.

Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.

D. V. Von Hoff, M. Villalona-Calero, L. Schaaf, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

E. Winer, H. Rugo, P. LoRusso, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.

J. Verweij, J. Schellens, D. V. Von Hoff, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours.

J. Verweij, J. Schellens, D. V. Von Hoff, 1998, European journal of cancer.

A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea

G. Weiss, S. Hilsenbeck, D. V. Hoff, 1998 .

Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy

B. Pollock, L. Smith, S. Kalter, 2005, Breast Cancer Research and Treatment.

Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.

G. Weiss, D. V. Von Hoff, H. Burris, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Denosumab versus zoledronic acid (ZA) for the treatment of bone metastases: An integrated analysis of results from 2 randomized, double-blind, phase 3 trials

Chunlei Ke, Alison T Stopeck, David H. Henry, 2011 .

Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.

J. Verweij, J. Schellens, D. V. Von Hoff, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

927 A phase I and bioavailability study of oral topotecan

H. Burris, D. V. Hoff, J. Kuhn, 1995 .

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer

J. Hainsworth, L. Bosserman, H. Burris, 2017, Breast Cancer Research and Treatment.

First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.

J. Hainsworth, F. Greco, C. Scroggin, 2003, Clinical lymphoma.

Phase I study with the DNA sequence-specific agent adozelesin

D. V. Von Hoff, H. Burris, L. Schaaf, 1997, Anti-cancer drugs.

A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.

G. Weiss, D. V. Von Hoff, H. Burris, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A Phase I and Pharmacokinetic Study of Losoxantrone and Paclitaxel in Patients with Advanced Solid Tumors 1

G. Weiss, H. Burris, S. Baker, 1999 .

Fludarabine phosphate

G. Rodriguez, 2020, Investigational New Drugs.

Docetaxel in combination with fluorouracil: study design and preliminary results.

D. V. Von Hoff, P. Ravdin, H. Burris, 1997, Oncology.

A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion

G. Weiss, D. V. Von Hoff, G. Clark, 1998, Investigational New Drugs.

Phase I clinical trials of tezacitabine [(E)-2'-deoxy-2'-(fluoromethylene)cytidine] in patients with refractory solid tumors.

E. Orenberg, Richard E. Jones, G. Rodriguez, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

M. Buyse, N. Robert, M. Gnant, 2016, The Lancet. Oncology.

Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study

G. Scagliotti, M. Krzakowski, J. R. Pereira, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.

M. Gulley, D. V. Von Hoff, I. Ganly, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer

L. Bosserman, D. Slamon, B. Childs, 2014, SpringerPlus.

ER alpha genotypes and breast cancer recurrence

B. Pollock, L. Smith, S. Kalter, 2008 .

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

D. V. Von Hoff, S. Hilsenbeck, H. Burris, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of 96‐hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck. A southwest oncology group study

J. Ensley, M. Hussain, D. Schuller, 1995, Cancer.

A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)

J. Verweij, J. Schellens, D. V. Von Hoff, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma

P. Woolley, R. Gams, D. D. Hoff, 2004, Investigational new drugs.

Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer

L. Smith, C. Frei, L. B. Rangel, 2014, Breast Cancer Research and Treatment.

Phase II trial of docetaxel for cholangiocarcinoma.

R. Pazdur, H. Burris, P. Hoff, 1999, American journal of clinical oncology.

Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.

Howard, J. Hainsworth, R. Hermann, 2004, The oncologist.

Relationship between CYP2D6 and estrogen receptor alpha polymorphisms on tamoxifen metabolism in adjuvant breast cancer treatment.

B. Pollock, S. Kalter, R. Drengler, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.

W. Gradishar, J. Sparano, P. Ward, 2017, The oncologist.

Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck

Roy E. Smith, J. Ensley, D. Schuller, 1996, Investigational new drugs.

Phase I a nd P harmacologic S tudy o f P N401 a nd F luorouracil in P atients W ith A dvanced S olid M alignancies

M. Hidalgo, G. Weiss, M. Villalona-Calero, 2000 .

An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary.

J. Hainsworth, K. Fizazi, G. Daugaard, 2010 .